Endometrial Carcinoma Clinical Trial
Official title:
The Clinical Significance of Sentinel Lymph Node Imaging Combined With Imaging Examination in Pelvic and Peritoneal Lymphadenectomy for Endometrial Carcinoma
The aim of this prospective cohort study is to explore the clinical significance of sentinel lymph node imaging combined imaging examination evaluation in pelvic and peritoneal lymphadenectomy for endometrial carcinoma management.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | April 1, 2023 |
Est. primary completion date | March 15, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 10 Years to 90 Years |
Eligibility | Inclusion Criteria: 1. Females who are diagnosed with endometrial carcinoma; 2. Patients who are willing to receive primary non-reserved fertility function surgery to treat their disease; 3. Patients who are agreed to participated in this prospective cohort study. Exclusion Criteria: 1. Patients who still have the will to have pregnancy; 2. Patients who have other diseases or heavy injuries that will interfere with the results; 3. Simultaneous participation in another clinical study with investigational medicinal product(s) or researcher thinks the subjects are not suitable for this trial. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital of Wenzhou Medical University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the number (s) of pelvic and abdominal lymph node metastasis | the specific number of pelvic and abdominal lymph nodes that are invaded by metastatic endometrial carcinoma | 1 year during the perioperative period | |
Primary | the percentage (%) of pelvic and abdominal lymph node metastasis | the specific percentage of pelvic and abdominal lymph nodes that are invaded by metastatic endometrial carcinoma | 1 year during the perioperative period | |
Primary | the coincidence rate (%) of pelvic and abdominal lymph node imaging, sentinel lymph node imaging and pathological diagnosis | by performing chi-square test by SPSS 17.0,we plan to calculate the coincidence rate of three clinical examination | 1 year during the perioperative period | |
Primary | the effect of pelvic lymphadenectomy on the prognosis of endometrial carcinoma patients | by setting up the control group and experimental group and conducting follow-up,we are determined to know whether pelvic lymphadenectomy would influence the prognosis of endometrial carcinoma | 1 year during the perioperative period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00756847 -
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
|
Phase 1 | |
Completed |
NCT00729586 -
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT02983279 -
Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer
|
N/A | |
Completed |
NCT02017353 -
Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00997373 -
Letrozole as a Treatment of Endometrial Cancer
|
N/A | |
Recruiting |
NCT04851119 -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04576104 -
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06102252 -
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma
|
N/A | |
Active, not recruiting |
NCT02598219 -
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
|
Phase 3 | |
Recruiting |
NCT04159155 -
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05139368 -
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
|
N/A | |
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 | |
Suspended |
NCT06253494 -
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03917381 -
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03372720 -
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
|
N/A | |
Recruiting |
NCT06413992 -
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05316467 -
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
|
Phase 2/Phase 3 |